tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kay JE et al. | Uptake of FK 506 by lymphocytes and erythrocytes. | 1991 | Transplant. Proc. | pmid:1721269 |
| Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
| Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
| Abu-Elmagd KM et al. | Strategy of FK 506 therapy in liver transplant patients: effect of graft function. | 1991 | Transplant. Proc. | pmid:1721272 |
| Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
| Rao P et al. | Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. | 1991 | Transplant. Proc. | pmid:1721301 |
| DiLella AG and Craig RJ | Characterization of the human FKBP-12 gene and related pseudogenes. | 1991 | Transplant. Proc. | pmid:1721302 |
| Kar S and Carr B | Gene expression of FK 506-binding protein. | 1991 | Transplant. Proc. | pmid:1721303 |
| Connelly PR | Thermodynamics of interaction of FK 506-binding protein and its ligands. | 1991 | Transplant. Proc. | pmid:1721304 |
| Fung J et al. | A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. | 1991 | Transplant. Proc. | pmid:1721333 |
| Winkler M et al. | Use of FK 506 for treatment of chronic rejection after liver transplantation. | 1991 | Transplant. Proc. | pmid:1721334 |
| D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
| Lewis WD et al. | FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. | 1991 | Transplant. Proc. | pmid:1721336 |
| Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
| Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
| Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721367 | |
| Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
| Darras FS et al. | Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721368 |
| Shapiro R et al. | Kidney transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703352 |
| Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
| Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
| Eidelman BH et al. | Neurologic complications of FK 506. | 1991 | Transplant. Proc. | pmid:1721398 |
| DiMartini A et al. | Psychiatric morbidity in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721399 |
| de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
| Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
| Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
| Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
| de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
| Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
| Gotoh M et al. | Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1721431 |
| Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
| McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
| Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
| Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
| Deguchi K et al. | Effects of FK 506 on acute experimental allergic encephalomyelitis. | 1991 | Transplant. Proc. | pmid:1721461 |
| Bolton C | The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. | 1991 | Transplant. Proc. | pmid:1721462 |
| McManus BM et al. | Impact of FK 506 on myocarditis in the enteroviral murine model. | 1991 | Transplant. Proc. | pmid:1721463 |
| Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
| Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
| Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |
| Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
| Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |
| Lane WS et al. | Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. | 1991 | J. Protein Chem. | pmid:1718307 |
| Goto S et al. | Effect of FK 506 and cyclosporine on heart allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1703700 |